BioStock: Impactful third quarter for Cereno

Swedish biotech Cereno Scientific has delivered a transformative Q3 2024, highlighted by positive phase IIa results for its lead candidate, CS1. Backed by a series of significant milestones, a strengthened focus on rare diseases and a recent SEK 250 million capital injection, Cereno is decisively advancing towards key milestones in 2025. At the same time, the company is progressing business development activities, actively evaluating potential partners for its pipeline of development.

Read the article at biostock.se:

https://www.biostock.se/en/2024/11/impactful-third-quarter-for-cereno/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/